- Home
- AMZE vs BCAB Comparison
AMZE vs BCAB Comparison
Compare AMZE & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMZE | BCAB |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | United States | United States |
| Employees | 28 | N/A |
| Industry | Beverages (Production/Distribution) | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 6.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AMZE | BCAB |
|---|---|---|
| Price | $0.13 | $3.67 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 6.9M | 48.4K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | $1,986.62 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $0.12 |
| 52 Week High | $11.70 | $6.52 |
Technical Indicators
Market Signals| Indicator | AMZE | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 44.95 | 48.67 |
| Support Level | $0.12 | $3.24 |
| Resistance Level | $0.20 | $6.33 |
| Average True Range (ATR) | 0.01 | 0.37 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 24.60 | 45.46 |
Price Performance
Historical ComparisonAbout AMZE Amaze Holdings Inc.
Amaze Holdings Inc is a technology-enabled, creator-powered commerce platform that enables creators, brands, and consumers to transact at scale. The Company provides infrastructure for creators and brands to design, launch, market, and fulfill products. The Company operates in two segments: E-commerce / Subscriptions, which includes the Amaze platform and creator commerce operations supporting product sales, subscription offerings, and digital content delivery; and Wine Products, which includes the sale of Fresh Vine wines through wholesale and direct-to-consumer channels across the United States and Puerto Rico.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.